SCHEMBL25546356

SCHEMBL25546356

CCCOc1cccc(-c2nc(Cl)sc2CC(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
FBP1 P09467 2/20 0.43
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
CYP1A2 P05177 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CTSA P10619 1/20 0.38
ERN1 O75460 1/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
HTT P42858 2/20 0.36
TP53 P04637 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546513 0.94 SMN1; SMN2 (0.47) KDM4EFBP1KMT2AMEN1SMN1; SMN2
SCHEMBL25546032 0.91 KMT2A (0.47) KDM4EFBP1MAPTKMT2AMEN1
SCHEMBL25546355 0.90 FBP1 (0.42) KDM4EFBP1KMT2ASMN1; SMN2CYP1A2
SCHEMBL25546364 0.90 FBP1 (0.45) KDM4EFBP1KMT2ASMN1; SMN2CYP1A2
SCHEMBL25557028 0.87 KDM4E (0.47) KDM4EFBP1MAPTKMT2AMEN1
SCHEMBL25546408 0.86 SMN1; SMN2 (0.41) KDM4EFBP1MAPTKMT2ASMN1; SMN2
SCHEMBL25545933 0.85 TDP1 (0.44) KDM4EFBP1MAPTSMN1; SMN2ALDH1A1
SCHEMBL25546361 0.84 FBP1 (0.43) FBP1MAPTKMT2AMEN1LMNA
SCHEMBL25546349 0.84 FBP1 (0.39) FBP1KMT2ACYP2C9CYP2C19CTSA
SCHEMBL25546359 0.84 PDE4B (0.44) FBP1KMT2AMEN1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 KDM4E 710/4885FBP1 735/4885MAPT 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.